Vyne Total Liab vs Long Term Debt Analysis

VYNE Stock  USD 2.97  0.40  15.56%   
Vyne Therapeutics financial indicator trend analysis is much more than just breaking down Vyne Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vyne Therapeutics is a good investment. Please check the relationship between Vyne Therapeutics Total Liab and its Long Term Debt accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.

Total Liab vs Long Term Debt

Total Liab vs Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vyne Therapeutics Total Liab account and Long Term Debt. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Vyne Therapeutics' Total Liab and Long Term Debt is 0.42. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of Vyne Therapeutics, assuming nothing else is changed. The correlation between historical values of Vyne Therapeutics' Total Liab and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Vyne Therapeutics are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Total Liab i.e., Vyne Therapeutics' Total Liab and Long Term Debt go up and down completely randomly.

Correlation Coefficient

0.42
Relationship DirectionPositive 
Relationship StrengthWeak

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Long Term Debt

Long-term debt is a debt that Vyne Therapeutics has held for over one year. Long-term debt appears on Vyne Therapeutics balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Vyne Therapeutics balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.
Most indicators from Vyne Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vyne Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.At present, Vyne Therapeutics' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 0.23, whereas Issuance Of Capital Stock is forecasted to decline to about 347.7 K.
 2021 2022 2023 2024 (projected)
Gross Profit11.4M477K424K402.8K
Total Revenue14.8M477K424K402.8K

Vyne Therapeutics fundamental ratios Correlations

0.530.580.82-0.02-0.370.540.210.930.590.35-0.520.380.38-0.460.99-0.230.68-0.520.380.44-0.740.30.340.140.64
0.530.90.560.06-0.80.790.380.220.820.39-0.630.790.77-0.450.490.20.37-0.640.730.81-0.470.960.930.82-0.24
0.580.90.550.29-0.740.950.130.280.790.33-0.50.810.73-0.380.530.10.59-0.80.760.75-0.650.860.850.63-0.14
0.820.560.55-0.23-0.610.550.30.760.750.58-0.890.460.65-0.880.820.050.46-0.620.280.68-0.750.390.450.150.5
-0.020.060.29-0.23-0.150.19-0.79-0.150.060.110.310.240.130.36-0.110.060.37-0.320.240.12-0.180.130.180.13-0.05
-0.37-0.8-0.74-0.61-0.15-0.65-0.08-0.14-0.88-0.790.75-0.81-0.990.63-0.34-0.39-0.430.82-0.44-0.990.62-0.84-0.88-0.60.11
0.540.790.950.550.19-0.650.090.270.710.25-0.490.760.64-0.410.50.030.57-0.730.590.64-0.650.760.710.45-0.1
0.210.380.130.3-0.79-0.080.090.170.17-0.06-0.36-0.040.09-0.310.27-0.12-0.280.090.360.130.150.310.260.42-0.15
0.930.220.280.76-0.15-0.140.270.170.390.28-0.420.150.17-0.420.96-0.270.61-0.350.10.22-0.67-0.030.04-0.170.83
0.590.820.790.750.06-0.880.710.170.390.56-0.80.780.86-0.720.570.350.47-0.860.550.87-0.750.770.840.51-0.03
0.350.390.330.580.11-0.790.25-0.060.280.56-0.620.40.82-0.550.340.090.37-0.580.060.82-0.490.410.520.290.33
-0.52-0.63-0.5-0.890.310.75-0.49-0.36-0.42-0.8-0.62-0.56-0.780.96-0.52-0.34-0.190.57-0.23-0.780.57-0.55-0.57-0.31-0.14
0.380.790.810.460.24-0.810.76-0.040.150.780.4-0.560.77-0.410.340.570.64-0.770.390.78-0.710.770.740.44-0.18
0.380.770.730.650.13-0.990.640.090.170.860.82-0.780.77-0.680.350.350.42-0.820.430.99-0.620.810.860.58-0.06
-0.46-0.45-0.38-0.880.360.63-0.41-0.31-0.42-0.72-0.550.96-0.41-0.68-0.47-0.3-0.130.54-0.14-0.660.56-0.37-0.42-0.12-0.2
0.990.490.530.82-0.11-0.340.50.270.960.570.34-0.520.340.35-0.47-0.230.66-0.50.340.41-0.730.250.30.090.66
-0.230.20.10.050.06-0.390.03-0.12-0.270.350.09-0.340.570.35-0.3-0.230.07-0.330.00.33-0.250.250.230.06-0.37
0.680.370.590.460.37-0.430.57-0.280.610.470.37-0.190.640.42-0.130.660.07-0.710.20.44-0.870.260.29-0.050.49
-0.52-0.64-0.8-0.62-0.320.82-0.730.09-0.35-0.86-0.580.57-0.77-0.820.54-0.5-0.33-0.71-0.54-0.810.86-0.64-0.73-0.33-0.07
0.380.730.760.280.24-0.440.590.360.10.550.06-0.230.390.43-0.140.340.00.2-0.540.46-0.240.720.740.78-0.32
0.440.810.750.680.12-0.990.640.130.220.870.82-0.780.780.99-0.660.410.330.44-0.810.46-0.630.830.870.61-0.03
-0.74-0.47-0.65-0.75-0.180.62-0.650.15-0.67-0.75-0.490.57-0.71-0.620.56-0.73-0.25-0.870.86-0.24-0.63-0.35-0.420.03-0.45
0.30.960.860.390.13-0.840.760.31-0.030.770.41-0.550.770.81-0.370.250.250.26-0.640.720.83-0.350.970.88-0.44
0.340.930.850.450.18-0.880.710.260.040.840.52-0.570.740.86-0.420.30.230.29-0.730.740.87-0.420.970.87-0.36
0.140.820.630.150.13-0.60.450.42-0.170.510.29-0.310.440.58-0.120.090.06-0.05-0.330.780.610.030.880.87-0.52
0.64-0.24-0.140.5-0.050.11-0.1-0.150.83-0.030.33-0.14-0.18-0.06-0.20.66-0.370.49-0.07-0.32-0.03-0.45-0.44-0.36-0.52
Click cells to compare fundamentals

Vyne Therapeutics Account Relationship Matchups

Vyne Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets79.2M93.7M67.0M40.8M97.7M82.0M
Other Current Liab485K15.2M11.2M7.0M5.6M5.6M
Total Current Liabilities10.7M21.5M18.4M9.3M7.5M10.9M
Total Stockholder Equity68.5M37.5M48.6M31.2M88.7M93.2M
Net Debt(30.1M)(22.8M)(41.9M)(31.3M)(30.4M)(31.9M)
Retained Earnings(184.3M)(566.2M)(639.5M)(662.7M)(691.3M)(656.8M)
Accounts Payable3.8M4.8M6.5M2.4M1.7M3.3M
Cash30.8M57.6M42.3M30.9M30.6M36.6M
Cash And Short Term Investments136.3M76.9M58.6M42.3M93.3M70.3M
Common Stock Shares Outstanding471.4K1.8M2.9M3.2M10.3M10.8M
Liabilities And Stockholders Equity79.2M93.7M67.0M40.8M97.7M82.0M
Non Current Liabilities Total34.3M34.8M6.9M211K1.4M1.3M
Other Current Assets1.4M4.6M6.1M7.2M2.7M3.6M
Other Stockholder Equity252.8M603.7M688.2M692.3M780.0M819.0M
Total Liab10.7M56.2M18.4M9.6M9.0M8.5M
Total Current Assets78.3M87.3M63.2M38.3M96.0M78.4M
Other Liab1.4M1.1M880K769K884.4K997.5K
Net Tangible Assets17.6M37.5M48.6M31.2M28.1M48.6M
Property Plant And Equipment Net769K2.1M354K282K207K196.7K
Non Current Assets Total842K6.5M3.9M2.5M1.7M2.9M
Non Currrent Assets Other73K4.3M3.5M2.2M1.5M1.6M
Other Assets744K4.9M3.5M2.5M2.9M1.9M
Net Receivables135K15.8M7.6M5.2M5.9M5.3M
Short Term Investments86.7M46.2M1.0M0.062.6M65.8M
Property Plant And Equipment Gross98K2.1M354K0.0207K412.2K
Accumulated Other Comprehensive Income(51K)(96K)24K26K29.9K31.4K
Non Current Liabilities Other22K7K457K1.3M1.5M1.6M
Property Plant Equipment2.2M4.6M2.1M354K318.6K302.7K
Net Invested Capital68.5M70.7M48.6M31.2M88.7M59.9M
Net Working Capital67.7M65.8M44.8M28.9M88.4M55.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Vyne Therapeutics is a strong investment it is important to analyze Vyne Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Vyne Therapeutics' future performance. For an informed investment choice regarding Vyne Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
1.72
Revenue Per Share
0.016
Quarterly Revenue Growth
0.467
Return On Assets
(0.35)
Return On Equity
(0.60)
The market value of Vyne Therapeutics is measured differently than its book value, which is the value of Vyne that is recorded on the company's balance sheet. Investors also form their own opinion of Vyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vyne Therapeutics' market value can be influenced by many factors that don't directly affect Vyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.